Table 1.
n | Entire cohort | Spinal patients | PA | APPA | Difference PA versus APPAa | |
---|---|---|---|---|---|---|
1157 | 343 | 250 | 93 | |||
Primary tumor | n.s. | |||||
Breast cancer | 451 (39%) | 145 (42%) | 110 (44%) | 35 (38%) | ||
Prostate cancer | 267 (23%) | 83 (24%) | 63 (25%) | 20 (22%) | ||
Lung cancer | 287 (25%) | 68 (20%) | 48 (19%) | 20 (22%) | ||
Other | 152 (13%) | 47 (14%) | 29 (12%) | 18 (19%) | ||
Age | n.s. | |||||
≤ 65 years | 565 (49%) | 167 (49%) | 120 (48%) | 47 (51%) | ||
> 65 years | 592 (51%) | 176 (51%) | 130 (52%) | 46 (50%) | ||
Gender | n.s. | |||||
Male | 624 (54%) | 178 (52%) | 125 (50%) | 53 (57%) | ||
Female | 533 (46%) | 165 (48%) | 125 (50%) | 40 (43%) | ||
KPS | n.s. | |||||
90–100 | 221 (19%) | 67 (20%) | 47 (19%) | 20 (22%) | ||
70–80 | 587 (51%) | 176 (51%) | 132 (53%) | 44 (47%) | ||
20–60 | 343 (30%) | 100 (29%) | 71 (28%) | 29 (31%) | ||
Pain score | n.s. | |||||
2–4 | 234 (20%) | 71 (21%) | 54 (22%) | 17 (18%) | ||
5–7 | 550 (48%) | 155 (45%) | 116 (46%) | 39 (42%) | ||
8–10 | 366 (32%) | 117 (34%) | 80 (32%) | 37 (40%) | ||
Visceral metastases | n.s. | |||||
No | 838 (72%) | 247 (72%) | 178 (71%) | 69 (74%) | ||
Yes | 319 (28%) | 96 (28%) | 72 (29%) | 24 (26%) | ||
Systemic therapy | 0.009 | |||||
No | 531 (46%) | 156 (46%) | 103 (41%) | 53 (57%) | ||
Yes | 626 (54%) | 187 (55%) | 147 (59%) | 40 (43%) | ||
Treatment schedule | n.s. | |||||
1 × 8 Gy | 578 (50%) | 171 (50%) | 129 (52%) | 42 (45%) | ||
6 × 4 Gy | 579 (50%) | 172 (50%) | 121 (48%) | 51 (55%) | ||
Pain medication | n.s. | |||||
No opioids | 667 (58%) | 170 (50%) | 123 (49%) | 47 (51%) | ||
Opioids | 490 (42%) | 173 (50%) | 127 (51%) | 46 (50%) | ||
Spinal localization | n.s. | |||||
Thoracic spine | 117 (34%) | 90 (36%) | 27 (29%) | |||
Thoraco-lumbar spine | 32 (9%) | 27 (11%) | 5 (5%) | |||
Lumbar spine | 183 (53%) | 124 (50%) | 59 (63%) | |||
Lumbo-sacral spine | 11 (3%) | 9 (4%) | 2 (2%) |
PA, Posterior-anterior field; APPA, Anterior-posterior and posterior-anterior field; KPS, Karnofsky performance score; Gy, Gray; n.s., not significant
aChi-square